BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $570,382 | -33.5% | 15,113 | -19.7% | 0.02% | -37.5% |
| Q2 2023 | $857,563 | +10.3% | 18,823 | -1.8% | 0.03% | 0.0% |
| Q1 2023 | $777,439 | +39.3% | 19,168 | +75.0% | 0.03% | +6.7% |
| Q4 2022 | $558,163 | -62.3% | 10,951 | -60.2% | 0.03% | -70.3% |
| Q3 2022 | $1,481,000 | +185.9% | 27,498 | +241.1% | 0.10% | +180.6% |
| Q2 2022 | $518,000 | -67.5% | 8,062 | -60.7% | 0.04% | -67.3% |
| Q1 2022 | $1,592,000 | +11.7% | 20,527 | +23.6% | 0.11% | 0.0% |
| Q4 2021 | $1,425,000 | +15.7% | 16,601 | +8.3% | 0.11% | -12.7% |
| Q3 2021 | $1,232,000 | +141.6% | 15,322 | +141.8% | 0.13% | +103.2% |
| Q2 2021 | $510,000 | -25.7% | 6,336 | -22.1% | 0.06% | -49.2% |
| Q1 2021 | $686,000 | +17.5% | 8,134 | +11.7% | 0.12% | -20.8% |
| Q4 2020 | $584,000 | +164.3% | 7,279 | +164.9% | 0.15% | +81.2% |
| Q3 2020 | $221,000 | -2.2% | 2,748 | +4.6% | 0.08% | -34.1% |
| Q2 2020 | $226,000 | -9.6% | 2,628 | -14.5% | 0.13% | -38.3% |
| Q1 2020 | $250,000 | -33.0% | 3,075 | -31.1% | 0.21% | -23.7% |
| Q4 2019 | $373,000 | – | 4,460 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |